Therapeutical Attitude and Analysis of Results in Brain Metastases
Objectives - The aim of this study is to assess therapeutic outcomes in patients presenting with brain metastases as the first manifestation of malignancies either as a final stage in the evolution of malignancies. Materials and methods - We've performed a complex retrospective study on a total of 81 patients with brain metastases treated in Medical Oncology Clinic of the Emergency County Hospital Craiova between 1 January 2005-31 December 2010. Results - The average age of women (55 years) was statistically significantly low compared to men (64 years) (p = 0.000). The most affected age group was 51-60 years in women with maximum frequency of breast cancer and 61-70 years for men, with predominance of lung cancer. Most cases were presented with multiple metastases (90.12%) and the average latency-free interval from primary tumor detection to onset of symptoms was 29.8 months. Clinical manifestations, in most cases, occurred in less than 6 months after diagnosis of the primary tumor being a consequence of the evolution of disease at distance (36 patients / 62 patients in oncological evidence 58.06%) and 12 months after diagnosis survival rate was low being detected in patients with a controlled primary tumor and distant resumption of the disease (14 patients / 62 patients in oncological evidence-22.58%).Median survival in patients with irradiated brain metastases was 7 months. Multivariate statistical analysis of the survival rate has detected statistically significant differences depending on the type of the primary tumor (p = 0.000) and the manner of the onset of brain metastases as the first manifestation or evolution of neoplastic disease (p = 0.000).Survival was affected, without statistical significance threshold, by the number of metastases, patient gender and the loco-regional status of the primary tumor.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
Current health sciences journal - 42(2016), 4 vom: 20. Okt., Seite 372-384 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Crisan, A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Brain metastases |
---|
Anmerkungen: |
Date Revised 04.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.12865/CHSJ.42.04.07 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM29210975X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM29210975X | ||
003 | DE-627 | ||
005 | 20240404232232.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.12865/CHSJ.42.04.07 |2 doi | |
028 | 5 | 2 | |a pubmed24n1364.xml |
035 | |a (DE-627)NLM29210975X | ||
035 | |a (NLM)30581592 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Crisan, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Therapeutical Attitude and Analysis of Results in Brain Metastases |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 04.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Objectives - The aim of this study is to assess therapeutic outcomes in patients presenting with brain metastases as the first manifestation of malignancies either as a final stage in the evolution of malignancies. Materials and methods - We've performed a complex retrospective study on a total of 81 patients with brain metastases treated in Medical Oncology Clinic of the Emergency County Hospital Craiova between 1 January 2005-31 December 2010. Results - The average age of women (55 years) was statistically significantly low compared to men (64 years) (p = 0.000). The most affected age group was 51-60 years in women with maximum frequency of breast cancer and 61-70 years for men, with predominance of lung cancer. Most cases were presented with multiple metastases (90.12%) and the average latency-free interval from primary tumor detection to onset of symptoms was 29.8 months. Clinical manifestations, in most cases, occurred in less than 6 months after diagnosis of the primary tumor being a consequence of the evolution of disease at distance (36 patients / 62 patients in oncological evidence 58.06%) and 12 months after diagnosis survival rate was low being detected in patients with a controlled primary tumor and distant resumption of the disease (14 patients / 62 patients in oncological evidence-22.58%).Median survival in patients with irradiated brain metastases was 7 months. Multivariate statistical analysis of the survival rate has detected statistically significant differences depending on the type of the primary tumor (p = 0.000) and the manner of the onset of brain metastases as the first manifestation or evolution of neoplastic disease (p = 0.000).Survival was affected, without statistical significance threshold, by the number of metastases, patient gender and the loco-regional status of the primary tumor | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Brain metastases | |
650 | 4 | |a latency-free interval | |
650 | 4 | |a survival rate | |
650 | 4 | |a treatment | |
700 | 1 | |a Badulescu, F |e verfasserin |4 aut | |
700 | 1 | |a Popescu, M |e verfasserin |4 aut | |
700 | 1 | |a Andrei, I |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current health sciences journal |d 2009 |g 42(2016), 4 vom: 20. Okt., Seite 372-384 |w (DE-627)NLM237785471 |x 2067-0656 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2016 |g number:4 |g day:20 |g month:10 |g pages:372-384 |
856 | 4 | 0 | |u http://dx.doi.org/10.12865/CHSJ.42.04.07 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 42 |j 2016 |e 4 |b 20 |c 10 |h 372-384 |